Efficacy of probiotics in acute diarrhoea in children

Bhat, Sinchana; Shreekrishna, G N; Savio, C.

doi:10.18203/2349-3291.ijcp20182582

Cited by 15 publications

(15 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study also showed that both groups reduced the frequency of diarrhoea on Day 4 of treatment and statistically insignificant (p value=0.506). This result was consistent with the study conducted by Sinchana Bhat et al which showed that Bacillus Clausii did not significantly affect duration and frequency of diarrhoea in comparison to control and Saccharomyces Boulardii group 6 . This was supported by Canani RB et al evaluating five probiotic preparations in children with acute diarrhoea proved that only two preperations : L. rhamnosus (LGG) and the mix of (L bulgaricus, L acidophilus, S thermophilus and B bifidum) had a significant effect on reducing the severity and duration of diarrhoea after the first day of administration.…”

Section: Resultssupporting

confidence: 93%

Clinical Efficacy of Bacillus Clausii Probiotic in the Management of Acute Diarrhoea in Children

Hamid

Quaium

Rahman

et al. 2019

Chatt Maa Shi Hosp Med Coll J

View full text Add to dashboard Cite

Background: Diarrhoea is the second most common cause of under five mortality especially in developing world. Very few studies have been conducted so far on bacillus clausii probiotic with inconsistent result. So, the aim of the present study is to determine the clinical efficacy of Bacillus Clausii probiotic formulation as adjunct treatment of acute diarrhoea. Materials and methods: This prospective single blind randomized controlled trial included 310 infants and children between 6 months to 6 years of age admitted in a tertiary care hospital Sylhet, Bangladesh with acute watery diarrhoea having varied dehydration status ranging from no to severe dehydration excluding shocked state. Cases were randomly assigned to two groups: Group A (n=150) comprised of children who were treated with standard treatment (According to WHO guideline) only as control group and Group B who received standard treatment plus Bacillus Clausii as probiotic. Clinical responses were evaluated in terms of improvement of outcome variables such as duration and frequency of diarrhoea and duration of hospital stay. Results: Mean duration of diarrhoea was 3.3(±1.1) days in Group A and 3.2(±1.3) days in Group B which was not statistically significant. Frequency of diarrhoea decreased significantly at day 4 of treatment in both study groups showing no statistical difference. Mean duration of hospital stay in both groups was 3.8 days showing no significance. Conclusion: Bacillus Clausii is ineffective in reducing the duration, frequency of diarrhoea and duration of hospital stay. Chatt Maa Shi Hosp Med Coll J; Vol.18 (1); Jan 2019; Page 14-17

show abstract

Section: Resultssupporting

confidence: 93%

Clinical Efficacy of Bacillus Clausii Probiotic in the Management of Acute Diarrhoea in Children

Hamid

Quaium

Rahman

et al. 2019

Chatt Maa Shi Hosp Med Coll J

View full text Add to dashboard Cite

show abstract

“…12 Another recent study conducted by Bhat S et al, which showed that Bacillus clausii did not significantly affect duration and frequency of diarrhoea in comparison to control and Saccharomyces boulardii group. 13 In this study, Bacillus clausii did not show any significant improvement in term of duration, frequency of diarrhoea and duration of hospital stay, but improved stool consistency one day later than that of multistrains group. Maugo BM conducting a study in under 5 children in Kenya concluded that there was a significant decrease in the frequency of stool on Day 3 and 4 of treatment but no significant difference in reduction of duration of diarrhoea and duration of hospital stay with Bacillus clausii.…”

Section: Discussioncontrasting

confidence: 51%

Comparative study of Bacillus clausii and multistrain probiotics in the management of acute diarrhoea in children

2019

View full text Add to dashboard Cite

Background: Diarrhoea is the second most common cause of under-five mortality especially in developing world. Many studies have been conducted so far using different probiotic strains with variable outcome. So, the aim of the present study was to compare the clinical efficacy of Bacillus clausii and multi strain probiotic formulation as adjunct treatment of acute diarrhoea.Methods: This prospective single blind randomized controlled clinical trial included 300 infants and children between 6 months to 6 years of age admitted in a tertiary care hospital Sylhet, Bangladesh with acute watery diarrhoea having varied dehydration status ranging from no to severe dehydration excluding shocked state. Cases were randomly assigned to three groups which were group I (n=100) comprised of children who were treated with standard treatment (according to WHO guideline) only as control group, group II (n=100) who received standard treatment plus Bacillus clausii and group III (n=100) who received standard treatment plus multi strain probiotic formulation (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophilus). Primary outcome variables were duration, frequency of diarrhoea and consistency of stool. Secondary outcome variable was duration of hospital stay.Results: Mean duration of diarrhoea was significantly shorter (p=0.001) in group III (2.62 days) compared to group I (3.26 days) and group II (3.22 days). Frequency of diarrhoea was significantly lower on day 3 of probiotic administration in group III (p <0.05) and on day 5 of treatment in group II (p <0.05). Stool consistency significantly improved on day 3 in group III (p <0.05) while it was on day 4 in group II. The duration of diarrhoea, hospital stay, stool consistency and frequency of stool on day 3 were not statistically significant (p >0.05) in group II in comparison to group I and group III.Conclusions: Multistrain probiotic formulation is effective in reducing the duration, frequency of diarrhoea and duration of hospital stay.

show abstract

“…Ultimately, 29 RCTs that randomised 4217 participants (2152 in the experimental group and 2065 in the control group) were included . .…”

Section: Resultsmentioning

confidence: 99%

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Szajewska

Kołodziej

Zalewski

2020

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background There is still controversy with regard to the efficacy of individual probiotic strains for the management of acute gastroenteritis. Aim To update evidence on use of Saccharomyces boulardii for treating acute gastroenteritis in children. Methods The Cochrane Library, MEDLINE and EMBASE databases were searched from inception to December 2019 for randomised controlled trials (RCTs) that compared use of S boulardii with no S boulardii (defined as placebo or no treatment). The grey literature was searched through Google search. Authors of the original papers and S boulardii manufacturers were contacted for additional data. Results Twenty‐nine RCTs (among them, 20 newly identified trials) were included. Only 38% of trials adequately generated their randomisation sequence, only 17% adequately concealed allocation and only one trial adequately blinded participants, study personnel and outcome assessors. However, 83% provided complete outcome data. None of the trials evaluated the effect of S boulardii on stool volume. Compared with placebo or no treatment, S boulardii use reduced the duration of diarrhoea (23 RCTs, n = 3450, mean difference −1.06 day, 95% CI −1.32 to −0.79; high heterogeneity [I2 = 90%]) (very low quality of evidence). S boulardii use was also associated with a reduced duration of hospitalisation (8 RCTs, n = 999, mean difference −0.85 day, 95% CI −1.35 to −0.34; I2 = 91%) (very low quality of evidence). S boulardii reduced the risk of diarrhoea on day 2 to day 7 (low quality of evidence). Conclusions In children with acute gastroenteritis, low‐ to very low‐quality evidence suggests that S boulardii confers a benefit for several diarrhoeal outcomes.

show abstract

Efficacy of probiotics in acute diarrhoea in children

Cited by 15 publications

References 11 publications

Clinical Efficacy of Bacillus Clausii Probiotic in the Management of Acute Diarrhoea in Children

Clinical Efficacy of Bacillus Clausii Probiotic in the Management of Acute Diarrhoea in Children

Comparative study of Bacillus clausii and multistrain probiotics in the management of acute diarrhoea in children

Systematic review with meta‐analysis: Saccharomyces boulardii for treating acute gastroenteritis in children—a 2020 update

Contact Info

Product

Resources

About